Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)22.30
  • Today's Change0.00 / 0.00%
  • Shares traded16.79k
  • 1 Year change+522.91%
  • Beta0.2609
Data delayed at least 15 minutes, as of Feb 18 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
ASSETS
Cash And Short Term Investments507541
Total Receivables, Net8.549.507.99
Total Inventory------
Prepaid expenses3.202.562.98
Other current assets, total0.000.000.00
Total current assets618752
Property, plant & equipment, net5.546.257.12
Goodwill, net------
Intangibles, net0.010.010.00
Long term investments0.410.300.29
Note receivable - long term------
Other long term assets0.00--0.00
Total assets679460
LIABILITIES
Accounts payable0.00----
Accrued expenses6.877.386.60
Notes payable/short-term debt000
Current portion long-term debt/capital leases4.925.024.56
Other current liabilities, total473727
Total current liabilities595038
Total long term debt464649
Total debt515153
Deferred income tax------
Minority interest------
Other liabilities, total280.320.27
Total liabilities1339687
SHAREHOLDERS EQUITY
Common stock1.421.411.05
Additional paid-in capital313313256
Retained earnings (accumulated deficit)(380)(317)(284)
Treasury stock - common(0.23)(0.23)(0.23)
Unrealized gain (loss)------
Other equity, total0.710.740.70
Total equity(66)(1.84)(27)
Total liabilities & shareholders' equity679460
Total common shares outstanding474735
Treasury shares - common primary issue0.020.020.02
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.